Email Updates

Search form

You are here


Oral tenofovir-based PrEP works. Faster, smarter rollout must be a top priority.

Recent clinical trials have shown clearly that daily, oral pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir and emtricitabine dramatically reduces the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit—if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal and incomplete. TDF/FTC is approved for use as oral PrEP in a handful of countries but, for maximum impact, PrEP rollout needs a coherent, global strategy involving many real-world demonstration projects, other research and guidance from global health agencies. At the same time, research into new PrEP formulations—such as intermittent use of pills or quarterly injections—could help improve adherence and achieve PrEP’s full potential.

What We're Reading

Aidsmap reports on a modeling study that found PrEP for men who have sex with men will be cost-effective in the UK within 40 years, and sooner if generics drive down prices.

October 17, 2017

Presenting at the International AIDS Society Conference, Bob Grant, principal investigator of the pioneering iPrEx PrEP study in gay men and transgender women, said there was abundant evidence that PrEP protects cisgender women from infection but it requires six to seven doses a week. That’s more than required for men and transgender women to achieve protection from HIV.

September 1, 2017

This CATIE News article presents brief summaries of some of the PrEP-related research presented at the 9th International AIDS Society (IAS) Conference on HIV Science held in Paris, France, in July 2017

August 23, 2017
Canadian AIDS Treatment Information Exchange
Subscribe to RSS - PrEP